Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals

Clinical Infectious Diseases

Volumn 27, Issue 4, 1998, Pages 901-902

  Tacconelli, Evelina ^a   Tumbarello, Mario ^a   De Gaetano, Katleen ^a   Cauda, Roberto ^a   Ortona, Luigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BACTEREMIA; COMBINATION CHEMOTHERAPY; FEMALE; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 2442737805     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/517165     Document Type: Article

References (4)

1. Deeks SG, Smith M, Holodniy, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277:145-53.
2. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11:1731-8.
3. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11:F101-5.
4. Tumbarello M, Tacconelli E, Caponera S, Cauda R, Ortona L. The impact of bacteraemia on HIV infection. Nine years experience in a large Italian university hospital. J Infect 1995; 31:123-31.